In this issue:
Adalimumab serum concentration guiding switch of bDMARD
Izokibep for active PsA
Mepolizumab in eosinophilic granulomatosis with polyangiitis
Retention rate of TNF vs IL-17 inhibitors in AS
bDMARD survival in late-onset axial SpA
Cancer risk of JAK inhibitors and bDMARDs
Guselkumab vs secukinumab for PsA
DMARDs for RA-associated interstitial lung disease
JAK inhibitors vs bDMARDs in RA
Secukinumab and enthesiophyte and erosion progression in PsA
Please login below to download this issue (PDF)